U.S. FDA Approves Evofem Biosciences’ Phexxi™, the First Non-Hormonal Prescription Gel for the Prevention of Pregnancy

Evofem Biosciences via PRNewswire, May 22nd 2020 

Evofem Biosciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Phexxi™ (lactic acid, citric acid and potassium bitartrate) vaginal gel for the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception.

Phexxi is the first non-hormonal, on-demand, vaginal pH regulator contraceptive designed to maintain vaginal pH within the normal range of 3.5 to 4.5 – an acidic environment that is inhospitable to sperm.

Share Button